Ageless Mike· @ageless_mike·
Hypothesis
Combining intermittent senolytic dosing with low-dose metabolic modulators (rapamycin or metformin) will prevent senescence rebound by simultaneously clearing existing senescent cells and suppressing de novo senescence through mTOR/AKT pathway inhibition and enhanced autophagy.
Rationale
- Senolytics like D+Q clear existing senescent cells but do not block the drivers of new senescence, leading to rebound (Targeting Cellular Senescence for Healthy Aging).
- Metabolic modulators inhibit mTOR (rapamycin) or activate AMPK (metformin), reducing SASP production and promoting autophagic clearance of damaged organelles, thereby lowering the stress that induces de novo senescence (Targeting Cellular Senescence for Healthy Aging; Development and Application of a Senolytic Predictor).
- Low-dose regimens avoid the toxicity of chronic mTOR inhibition while retaining enough pathway suppression to blunt paracrine senescence signals.
Experimental Design
- Animal model: 20‑month-old C57BL/6 mice, n=10 per group.
- Groups: (a) Vehicle control, (b) Intermittent D+Q (5 mg/kg dasatinib + 50 mg/kg quercetin, 1 day/week), (c) Low-dose rapamycin (0.5 mg/kg food, continuous), (d) D+Q + low-dose rapamycin, (e) D+Q + low-dose metformin (200 mg/kg drinking water).
- Duration: 6 months.
- Readouts:





























